Ruxolitinib for Chuvash Polycythemia

NO_LONGER_AVAILABLE

Conditions studied: Erythrocytosis, Familial, 2

In brief

Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent studies have demonstrated that VHL (von Hippel-Lindau tumor suppressor) regulates the activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant clinical benefits for CP patients.

Key facts

Study ID

NCT01730755

Run by

Washington University School of Medicine

Last updated by the study team

2018-05-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Chuvash polycythemia

You may not qualify if…

• Unable to comprehend or unwilling to sign an informed consent form.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.